Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5.
PURPOSE: An efficient adaptive immunity is critical for a longer survival in cancer. We investigated the prognostic value of tumor infiltration by CD8(+) T cells expressing the chemokine-receptor-7 (T(ccr7)) and the correlation between tumor infiltration by T(ccr7) and regulatory CD4(+)FoxP3(+) T cells (T(reg)) in 76 metastatic colorectal cancer (mCRC) patients enrolled in a phase III trial. EXPERIMENTAL DESIGN: T(ccr7) and T(reg) cell infiltration in tumor samples was quantified by immunohistochemistry. The correlation among T(ccr7), T(reg) tumor infiltration, and patients' outcome was evaluated. RESULTS: High T(ccr7) tumor infiltration was predictive of prolonged OS [high vs. low T(ccr7) score: median 38 months (95% CI: 24.5-51.4) vs. 20 months (95% CI: 11.4-28.5); HR = 0.48 (95% CI: 0.24-0.96); P = 0.03] and prolonged progression-free survival [PFS; high vs. low T(ccr7) score: median 12 months (95% CI: 7.7-16.2) vs. 7 months (95% CI: 5.2-8.7); HR = 0.54 (95% CI: 0.28-1.01); P = 0.01] after front-line chemotherapy. Regression analysis did not show correlation between T(ccr7) and T(reg) infiltration levels. However, the cluster of patients showing concomitant high infiltration by both T(ccr7) and T(reg) disclosed a favorable outcome [double high vs. double low tumor infiltration score: median OS = 35 months (95% CI: 20.8-49.1) vs. 17 months (95% CI: 4.6-29.3); HR = 0.32 (95% CI: 0.12-0.87); P = 0.02 and median PFS = 11 months (95% CI: 9.4-12.5) vs. 5 months (95% CI: 2.2-7.7); HR = 0.43 (95% CI: 0.17-1.06); P = 0.01]. CONCLUSIONS: High T(ccr7) tumor infiltration score is a favorable prognostic factor for mCRC. Our findings underline the relevance of microenvironment-related immunologic events for patient outcome.
目的:有效的适应性免疫对于癌症患者的长期生存至关重要。我们研究了在一项 III 期临床试验中入组的 76 例转移性结直肠癌(mCRC)患者的肿瘤浸润 CD8(+)T 细胞表达趋化因子受体-7(T(ccr7))的预后价值,以及 T(ccr7)与调节性 CD4(+)FoxP3(+)T 细胞(T(reg))肿瘤浸润之间的相关性。
实验设计:通过免疫组织化学定量检测肿瘤样本中 T(ccr7)和 T(reg)细胞的浸润。评估 T(ccr7)、T(reg)肿瘤浸润与患者预后之间的相关性。
结果:高 T(ccr7)肿瘤浸润预示着更长的总生存期[高 T(ccr7)评分组 vs. 低 T(ccr7)评分组:中位 38 个月(95%CI:24.5-51.4)vs. 20 个月(95%CI:11.4-28.5);HR=0.48(95%CI:0.24-0.96);P=0.03]和更长的无进展生存期[高 T(ccr7)评分组 vs. 低 T(ccr7)评分组:中位 12 个月(95%CI:7.7-16.2)vs. 7 个月(95%CI:5.2-8.7);HR=0.54(95%CI:0.28-1.01);P=0.01],这是在前一线化疗后观察到的。回归分析未显示 T(ccr7)和 T(reg)浸润水平之间存在相关性。然而,同时表现出 T(ccr7)和 T(reg)高浸润的患者亚群显示出有利的结局[双高组 vs. 双低组:中位总生存期=35 个月(95%CI:20.8-49.1)vs. 17 个月(95%CI:4.6-29.3);HR=0.32(95%CI:0.12-0.87);P=0.02]和更长的无进展生存期[中位无进展生存期=11 个月(95%CI:9.4-12.5)vs. 5 个月(95%CI:2.2-7.7);HR=0.43(95%CI:0.17-1.06);P=0.01]。
结论:高 T(ccr7)肿瘤浸润评分是 mCRC 的有利预后因素。我们的研究结果强调了微环境相关免疫事件对患者预后的重要性。
Clin Cancer Res. 2008-8-15
Eur J Cancer. 2013-10-5
Comput Struct Biotechnol J. 2024-10-5
Front Oncol. 2023-11-24
Front Cell Dev Biol. 2023-5-18
Am J Cancer Res. 2022-7-15